Justin M. Hall Esq. Net Worth

The estimated Net Worth of Justin Hall is at least $441 mil dollars as of 14 September 2022. Mr Hall owns over 10,000 units of Novabay Pharmaceuticals Inc stock worth over $39,864 and over the last 9 years he sold NBY stock worth over $0. In addition, he makes $400,720 as Pres, CEO, Gen. Counsel, Chief Compliance Officer y Corp. Sec. & Director at Novabay Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr Esq NBY stock SEC Form 4 insiders trading

Mr has made over 2 trades of the Novabay Pharmaceuticals Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 10,000 units of NBY stock worth $1,500 on 14 September 2022.

The largest trade he's ever made was buying 69,767 units of Novabay Pharmaceuticals Inc stock on 6 December 2021 worth over $30,000. On average, Mr trades about 8,863 units every 31 days since 2016. As of 14 September 2022 he still owns at least 83,172 units of Novabay Pharmaceuticals Inc stock.

You can see the complete history of Mr Hall stock trades at the bottom of the page.

Mr. Justin M. Hall Esq. biography

Justin M. Hall Esq. is the Pres, CEO, Gen. Counsel, Chief Compliance Officer, Corp. Sec. & Director at Novabay Pharmaceuticals Inc.

What is the salary of Mr Esq?

As the Pres, CEO, Gen. Counsel, Chief Compliance Officer y Corp. Sec. & Director of Novabay Pharmaceuticals Inc, the total compensation of Mr Esq at Novabay Pharmaceuticals Inc is $400,720. There are no executives at Novabay Pharmaceuticals Inc getting paid more.

How old is Mr Esq?

Mr Esq is 43, he's been the Pres, CEO, Gen. Counsel, Chief Compliance Officer y Corp. Sec. & Director of Novabay Pharmaceuticals Inc since . There are 6 older and 2 younger executives at Novabay Pharmaceuticals Inc. The oldest executive at Novabay Pharmaceuticals Inc is Paul Freiman, 81, who is the Independent Director.

What's Mr Esq's mailing address?

Justin's mailing address filed with the SEC is C/O NOVABAY PHARMACEUTICALS, INC., 2000 POWELL STREET, SUITE 1150, EMERYVILLE, CA, 94608.

Insiders trading at Novabay Pharmaceuticals Inc

Over the last 18 years, insiders at Novabay Pharmaceuticals Inc have traded over $3,799,939 worth of Novabay Pharmaceuticals Inc stock and bought 24,568,662 units worth $26,237,091 . The most active insiders traders include Pharma (Singapore) Pte. Ltd..., Pioneer Pharma Holdings Ltd... y Pharma (Hong Kong) Co Ltd P.... On average, Novabay Pharmaceuticals Inc executives and independent directors trade stock every 57 days with the average trade being worth of $127,779. The most recent stock trade was executed by Paul E. Freiman on 11 May 2023, trading 858 units of NBY stock currently worth $411.

What does Novabay Pharmaceuticals Inc do?

novabay pharmaceuticals $nby is a biopharmaceutical company focusing, commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global eye care market. novabay has two distinct product categories: the neutrox™ family of products, led by avenova™ for the eye care market, neutrophase® for wound care, and cellerx™ for the dermatology market; and aganocide® compounds, led by auriclosene™. novabay is commercializing avenova, a prescription lid and lash hygiene product for the management of the chronic eye conditions of blepharitis and meibomian gland dysfunction – also known as dry eye syndrome. these difficult-to-manage conditions affect approximately 30 million americans, with an annual market potential that novabay estimates at $500 million. novabay is gaining market traction with avenova through its 35-medical direct sales representatives under veteran leadership. avenova is available for order in 90% of all pharmacies across

Complete history of Mr Hall stock trades at Novabay Pharmaceuticals Inc

Novabay Pharmaceuticals Inc executives and stock owners

Novabay Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Justin M. Hall Esq.,
  Pres, CEO, Gen. Counsel, Chief Compliance Officer, Corp. Sec. & Director
• Justin Hall,
  President, Chief Executive Officer, Director
• Andrew Jones,
  Chief Financial Officer, Treasurer
• Swan Sit,
  Independent Director
• Yenyou Zheng,
  Independent Director
• Paul Freiman,
  Independent Director
• Mijia Wu,
  Director
• Xinzhou Li,
  Director
• Dr. Jeffrey Kunin M.D.,
  Pres of DERMAdoctor
• Dr. Audrey Kunin M.D.,
  Chief Product Officer
• Yongxiang Zheng,
  Director
• Julie Garlikov,
  Director
• Wang Xu,
  NEO - Sr Mgr and Controller
• Lewis J Stuart,
  Chief Commercial Officer
• Yanbin Liu,
  Director
• Jason Philip Raleigh,
  Interim CFO and Treasurer
• Xiaoyan Liu,
  Director
• Gail J Maderis,
  Director
• Todd Erik Zavodnick,
  Director
• Pharma (Singapore) Pte. Ltd...,
  10% owner
• T. Alex Mc Pherson,
  Director
• Thomas J Paulson,
  Chief Financial Officer
• Yonghao Ma,
  Director
• Jian Ping Fu,
  10% owner
• Massimo Radaelli,
  Director
• Mark M Sieczkarek,
  Director
• Pharma (Hong Kong) Co Ltd P...,
  10% owner
• John Joseph Mc Govern,
  Int Pres, CEO, CFO & Treasurer
• John James O'reilly,
  Chief Financial Officer
• Colin Scott,
  VP, Clinical Research & Dev't
• Keith R Bley,
  SVP Product Development
• Pioneer Pharma Holdings Ltd...,
  10% owner
• Roy J Wu,
  SVP Bus & Corp Development
• David W. Stroman,
  SVP, Ophthalmic Product Devt.
• Tony D.S. Wicks,
  Director
• Anthony Dailley,
  Director
• Robert R. Tufts,
  Director
• Charles Cashion,
  Director
• Behzad Khosrovi,
  VP, Research & Dev't
• Ramin Najafi,
  Chief Executive Officer
• Area Pioneer Pharma Co., Lt...,
  10% owner
• Ramin Najafi Family Trust D...,
  Chief Executive Officer
• Mark Brian Anderson,
  CSO
• Harry F Jr Hixson,
  Director
• Russell A. Hoon,
  Senior Vice President
• Xiaopei Wang,
  
• Jeffrey Kunin,
  President, DERMAdoctor, LLC
• Audrey Kunin,
  Chief Product Officer